Curcumin: a review

Monika Chauhan; Suman Saha; Amit Roy

Authors

Monika Chauhan Columbia Institute of Pharmacy, Vill. Tekari, Near Vidhan Sabha, Raipur (CG) 493111
Suman Saha Columbia Institute of Pharmacy, Vill. Tekari, Near Vidhan Sabha, Raipur (CG) 493111
Amit Roy Columbia Institute of Pharmacy, Vill. Tekari, Near Vidhan Sabha, Raipur (CG) 493111

Abstract

The main objective of this review article is to overcome or to improve the problems related with curcumin with the help of new technologies or modifications to make a promising therapeutic agent which gives a good therapeutic response. Curcumin, a known natural polyphenolic compound obtained from dietary spice turmeric, possesses pharmacologic effects including anti-inflammatory, antioxidant, and many other activities. Clinical trials on curcumin have shown its safety and efficacy even at high doses in humans. But inspite of that it shows poor bioavailability (oral bioavailability) which is one of the major problems regarding curcumin. There are other reasons contributing to the low plasma and tissue levels of curcumin appear to be due to poor absorption, rapid metabolism, and rapid systemic elimination. To improve the bioavailability of curcumin, numbers of approaches have been undertaken. These approaches involve, first, the use of adjuvant like piperine that interferes with glucuronidation; second, the use of liposomal curcumin; third, curcumin nanoparticles; fourth, the use of curcumin phospholipids complex; and fifth, the use of structural analogues of curcumin.

Downloads

Download data is not yet available.

References

Sharma R.A, Geschay A.J, Steward W.P. Curcumin: The story so far; European Journal of Cancer; 2005, 41; 1955-1968.

Brouk B. Plants consumed by man; New York; Academics press 1975:331.

Rajasekaran S.A.Therapeutic potential of curcumin in gastrointestinal diseases. World Journal of Gastrointestinal Pathophysiology; 2011; 15, 2(1):1-14.

Kim J; Lee K.W. Naturally occurring phytochemicals for the prevention of Alzheimer’s diseases; J. Neurochem 2010: 1415-1430.

Curcumin. Available from: http:// www.healthoracle.org.

Anand P, Kunnumakkara A.B, Newman R.A, Aggarwal B.B .Bioavailability of curcumin: Problem and promises, Review article; molecular pharmaceutics, 2007, 4 (6): 807-818.

Aggrawal B.B, Kumar A, Bharti A.C. Anticancer potentials of curcumin, preclinical and clinical studies, anticancer research 2003; 23(1):363-398.

Sharma R.A, Geschay A.J, Steward W.P. Curcumin: The story so far; European journal of Cancer; 41, 2005:1955-1968.

Lin J.K, Pan M.H, Shiau S.Y.L. Recent studies on the biofunctions and biotransformation of Curcumin, biofactors 2000, 13:153-158.

Wang Y.J, Pan M.H, Cheng A.L. Stability of curcumin in buffer solutions and characterization of its degradation products; J Pharm Biomed Anal 1997, 15: 1867-1876.

Pharmacopoeia of India, Published by the controller of Publication, Delhi, 3rd edn, II 1985:177.

Akram M, Shahab-Uddin, Ahmed A, Khan U, Hannan A, Mohiuddin E, Asif M .Curcuma longa and Curcumin: A review article, Rom J.Biol- Plant Biol, 55(2):65-70.

Wilken R, Veena M.S, Marilene B .Wang, Srivastaw E.S. Curcumin: A Review of anticancer properties and therapeutic activity in head and neck squamous cell carcinoma; Molecular cancer.2011, 10:12:1-19.

Stell P.M, Vokes E.E, Weichselbaum. Survival time in end-stage head and neck cancer. Eur J SurgicalOncol 1989, 15: 407-410.

Altekruse S.F, Kosary C.L, Krapcho M, Neyman N, Aminou R, Waldron W,Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner M.P, Lewis DR, Cronin K, Chen HS, Feuer E.J, Stinchcomb D.G, Edwards B.K: Seer Cancer Statistics Review 1975-2007.

Aggarwal S,Takadar V, Singh S, Myers J.N, Aggarwal B.B. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor kB signaling Int .cancer 2004; 111:679-692.

Lo Tempio M.M, Veena M.S, Steele H.L, Ramamurthy B, Ramalingam T.S, Colen A.N, Ch-krabati R, Srivatsan E.S, Wang M.B. Curcumin suppress growth of head and neck and sqamous cell carcinoma; clinical cancer; Res 2005; 11:6994-7002.

Wang D, Veena M.S, Sterenson K, Tang C, Ho B; Suh J.D, Duarte V.M, Faull K.F, Mehta K Srivatsan E.S, Wang M.B. Liposome encapsulated curcumin suppress growth of head and neck squamous cell carcinoma invitro and in xenografts through the inhibition of nuclear factor kappa B by an AKT independent pathway; clin cancer Res 2008; 14:6228-6236.

Mukhopadhay A, Bueso-Ramos, Chatterjee P, Pantazis P, Aggarwal B.B. Curcumin down Regulates cell survival mechanism in human prostate cancer cell lines, oncogenes 2001; 20: 7597-7609.

Mehta K, Pantazis P, Mcqueen T, Aggarwal B.B. Antiproliferative effect of curcumin against Human breast tumor cell lines; anticancer drugs 1997; 8:470-481.

Hanif R, Qiao L, Scniff S.J, Rigas B. Curcumin a natural plant phenolic food additive, inhibit Cell proliferation and induces cell cycle changes in colon, adenocarcinoma cell lines by a Prostaglandin independent pathway; J Lab clin Med 1997, 130:576-584.

Elattar T.M, Virji A.S.The inhibitory effect of curcumin, genistein, quercitine and cisplatin on the growth of oral cancer cell in vitro; anticancer Res 2000; 20:1733-1738.

Lin Y.G, Kunnumakkara .A.B, Nair A, Merritt W.M ,Han L.Y, Amaiz Pena G.N, Kamat A.A, Spanmuth W.A, Gershanson D.M, Lutgendorf S.K, Aggarwal B.B, Sood A.K. Curcumin inhibit tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor Kappa B pathway clin cancer Res 2007, 13:3423-3430.

Siwak D.R, Shishodia S, Aggarwal B.B, Kuzrock R, Curcumin induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of kappa B kinase and an independent of the B rat/mitogen activated/extracellular signal regular proteins kinase pathway and Akt pathway cancer 2005; 104:879-890.

Anand P, Sundaram C, Jhurani S, Kunnumakkara A.B, Aggarwal B.B, Curcumin and cancer: An ‘‘old-age” disease with an ‘‘age-old” solution Cytokine, 2008 ,267 ,2008 :133–164.

Rafiee P, Ogawa H, Heidemann J, Li M.S, Aslam M, Lamirand T.H, Fisher P.J, Graewin S.J, Dwinell M.B, Johnson C.P, Shaker R, Binion D.G. Isolation and characterization of human esophageal microvascular endothelial cells: mechanisms of inflammatory activation, Am. J. Physiol. Gastrointestinal. Liver Physiol. 285, 2003:1277– 1292.

Aggarwal B.B, Bhatt I.D, Ichikawa H, Ahn K.S, Sethi G, Sandur S.K, Sundaram C, Seeram N, Shishodia.S. Curcumin – biological and medicinal properties, 200:297–368.

Bansal S.S, Goyal M, Aquil F,Vadhanam M.V, Gupta R.C. Advanced Drug Delivery Systems of curcumin for cancer chemoprevention. Cancer Prev Res, 2011 4: 1158.

Bansal S.S, Vadhanam M.V, Gupta R.C. Development and invitro-in vivo evaluation of polymeric plants for continuous systemic delivery of curcumin Pharm Res 2011, 28:1121-30.

Ma Z Haddadi A,Malavio, Lavasanifar A, Lai R, Samuel J; Micelles of poly (ethylene oxide) –b-poly (epsilon- caprolactone) as vehicle for the solubilization, stabilization and controlled delivery of curcumin, J Biomed Mater Res A 2008:86:300-10.

Thangapazaham R.L, Puri A, Tele S, Blumenthal R, Maheshwari R.K. Evaluation of a nanotechnology based carrier for delivery of curcumin in prostate cancer cells Int J Oncology 2008; 32:1119-23.

Anand P, Nair H.B, Sung B, Kunnumakkara A.B, Yadav V.R, Tekmal R.R. Design of Curcumin loaded PLGA nano particles formulation with enhanced cellular uptake and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmcol 2010; 79: 330-8.

Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A, Polymeric nanoparticle encapsulated curcumin (nanocurcumin), novel strategy for human cancer therapy, J Nanobiotechnology 2007; 5: 3.

Shaikh J, Ankola D.D, Benival V, Singh D, Kumar M.N. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9 folds when compared to curcumin ad- ministered with piperine as absorption enhancer, Eur.J.Pharm Sci 2009; 37:223-30.

Ganta S, Amji M. Co administration of paciltaxel and curcumin in nanoemulsion formula- tion to overcome multidrug resistance in tumour cells.Mol.Pharm 2009; 6:928-39.

Maiti K, Mukherjee K, Gantait A, Saha B.P, Mukherjee P.K. Curcumin- phosphoplipid Complex, preparation, therapeutic evaluaton and pharmacokinetic study in rats; Int J Pharma 2007; 330:155-63.

Grabovac V, Bernkop.Schmuch. A Development and in vitro evaluation of surface modified Poly (lactide-co-glycolide) nanoparticle with chitosan -4 thiobutyl amidine. Drug Dev Ind Pharm 2007; 33: 767-74.

Hobbs S.K, Monsky W.L, Yuan F, Roberts W.G, Griffith L, Torchilin V.P. Regulation of transport pathways in tumor vessel: role of tumor type and micro-envoirnment.1998; 95:4607-12.

Yuan F, Dellian M, Fukumuua P, Leunig M, Berk D.A, Torchillin V.P. Vascular per-meability in a human tumor xenograft molecular size dependence and cut off size cancer Res 1995; 55:3752-6.

Gerlowski L.E, Jain R.K. Microvascular permeability of normal and neoplastic tissue Micr-ovase Res 1986; 31:288-305.

Birnboin S A, Del Vecchio P.J, Cooper J.A, Blumenstock F.A, Shephard J.M, Malik A.B. Molecular sieving characterstics of the cultured endothelial monolayer J Cell Physiol 1987; 132:111-7.

Thangapazaham R.L, Puri A, Tele S, Blumenthal R, Maheshwari R.K. Evaluation of a nan- otechnology based carrier for delivery of curcumin in prostate cancer cells Int J Oncology 2008; 32:1119-23.

Li L, Braiteh F.S, Kurzrock R. Liposome encapsulated curcumin, in vitro and in vivo effects on proliferation apoptosis, signaling and angiogenesis cancer 2005; 104:1322-3.

Jung S, Otberg N, Theide G, Richter H, Sterry W, Panzer S . Innovative liposomes as a transfollicular drug delivery system: penetration into porcine hair follicles .J invests Dermatol 2006; 126:1728:32.

Wattanakrai P, Suwanachote S, Kulkollakarn S, Rajatanavin N. The study of human skin irritation of a novel herbal skin care product and ingredients by human single closed patch testing. J Med Assoc Thai 2007; 90:1116–22.

Campbell RB, Ying B, and Kuesters GM, Hemphill R. Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics. J Pharm Sci 2009; 98:411– 29.

Lee MH, Lin HY, Chen HC, Thomas JL. Ultrasound mediates the release of curcumin from microemulsion Langmuir2008; 24:1707-13.

Santos P, Watkinson AC, Hadgraft J, Lane ME. Application of micro emulsions in dermal and transdermal drug delivery. Skin Pharmacol Physiol 2008; 21:246–59.

Teichmann A, Heuschkel S, Jacobi U, Presse G, and Neubert RH, Sterry W .Comparison of stratum corneum penetration and localization of a lipophilic model drug applied in an o/w microemulsion and an amphiphilic cream. Eur J Pharm Biopharm 2007; 67:699–706

Boriwanwattanarak P, Ingkaninan Khorana N, Viyoch J.Development of curcuminoids hydrogel patches using chitosan from various sources as controlled-release matrix. Int J 05–18.

Tiyaboonchai W, Tungpradit W, Plianbangchang P. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int J Pharm 2007; 337:299–306.

Domb AJ, Israel ZH, Elmalak O, Teomim D, Bentolila A. Preparation and characterization of carmustine loaded polyanhydride wafers for treating brain tumors. Pharm Res 1999; 16:762– -5.

Jain JP, Modi S, Domb AJ Kumar N. Role of polyanhydrides as localized drug carriers. J Control Release 2005; 103:541–63.

Langer R. Drug delivery and targeting. Nature 1998; 392:5–10.

Dash AK, Cudworth GC 2nd. Therapeutic applications of implantable drug delivery systems. J Pharmacol Toxicol Methods 1998; 40:1–12.

Asai A, Miyazawa T., Occurrence of orally administered curcuminoid as glucuronide and glucoronide / sulfate conjugates in rat plasma, Life-Sci. 2000; 67(23):2785-93.

Shankar T. N, Shantha N. V, Ramesh H. P, Murthy I. A, Murthy, V. S. Toxicity studies on turmeric (Curcuma longa): acute toxicity studies in rats, guinea pigs & monkeys. Indian J. Biol. 1980, 18 (1): 73–5.

Qureshi, S, Shah A. H, Ageel, A. M .Toxicity studies on Alpinia galanga and Curcuma longa. Planta Med. 1992, 58 (2): 124–7.

Lao, C. D, Demierre, M. F, Sondak, V. K. Targeting events in melanoma carcinogenesis for the prevention of melanoma. Expert ReV. Anticancer Ther. 2006, 6 (11): 1559–68.

Lao, C. D, Ruffin, M. T, Normolle, D, Heath, D. D, Murray, S. I, Bailey, J. M, Boggs, M. E., Crowell, J, Rock, C. L., Brenner, D. E. Dose escalation of a curcuminoid formulation. BMC Complement Altern. Med. 2006, 6:10.

Cheng A. L, Hsu C. H., Lin J. K, Hsu M. M, Ho Y. F, Shen T. S, Ko J. Y, Lin J. T, Lin B. R., Ming-Shiang W, Yu H. S, Jee S. H, Chen G. S, Chen T. M, Chen C. A, Lai M. K., Pu Y. S, Pan M. H, Wang Y. J, Tsai C. C, Hsieh C. Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001, 21 (4):2895–900.

Shoba. G, Joy. D, Joseph. T, Majeed. M, Rajendran. R, Srinivas P. S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998, 64(4):353–6.

Aggarwal B. B, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. AdV. Exp. Med. Biol. 2007, 595:1–75.

Aggarwal, B. B, Kumar A, Bharti A. C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003, 23 (1):363–98.

Hsu, C. H, Cheng A. L. Clinical studies with curcumin. AdV.Exp. Med. Biol. 2007, 595:471–80.

Wahlstrom, B, Blennow, G. A study on the fate of curcumin in the rat. Acta Pharmacol.Tox- -icol. (Copenhagen) 1978, 43 (2): 86–92.

Rajasekaran SA. Therapeutic potential of curcumin in gastrointestinal diseases. World J Gastrointest Pathophysiol 2011; 2(1): 1-14

Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 2007; 4: 807-818.

Aggarwal B.B, Harikumar B.Kuzhuvelil, Potential therapeutic effects of curcumin the anti inflammatory agent, against neurogenerative, cardiovascular, pulmonary, metabolic autoimmune and neoplastic diseases; 2008,41:40-59.

Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS. Phase I clinical trial of curcumin, a chemo preventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001; 21:2895–900.

Lao CD, Ruffin M.T.T, Normolle D, Heath DD, Murray SI, Bailey JM. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006; 6:10.

Shishu, Maheshwari M. Comparative bioavailability of curcumin, turmeric and BiocurcumaxTM in traditional vehicles using non-everted rat intestinal sac model. J Func Foods 2010; 2: 60-65.

Kang MJ, Cho JY, Shim BH, Kim DK, Lee J. Bioavailability enhancing activities of natural compounds from medicinal plant. J Med Plants Res 2009; 3: 1204-1211.

Balasubramanian S, Eckert RL. Green tea polyphenol and curcumin inversely regulate human involucrin promoter activity via opposing effects on CCAAT/enhancer-binding protein function. J Biol Chem 2004; 279: 24007-24014.

Chiao CS, Robinson JR. Sustained- Release Drug Delivery Systems. 1995: (2):1660-75.

Kant Shashi, Kumar Satinder, Prashant Bharat. A complete Review on: Liposome; ISSN 2230-8407: 10-16.

Crommelin D.J.A, Lasic D.D, papahadjopoulos D. Liposome, revisited Science 1995 267: 1275-1276.

Emanuel N, Kedar E, Bolotin E.M, Smorodinsky N.I, Barenhotz V, 1996.Preparation & Characterization of doxorubicin loaded stearically stabilized immunoliposomes Pharm Res 13: :352-359.

DIY Scientist. Increasing the bioavailability of curcumin through Liposomal Encapsulation June 1, 2011.

Vyas S.P, Khar R.K. Targeted & Controlled Drug Delivery; section II Carrier concepts in Drug Delivery, chapter 5, liposomes; CBS publishers &Distributers first edition 2002:173-248.

Vila A, Sanchez A, Tobio M, Calvo P, Alonso MJ. Design of biodegradable particles for protein delivery. J Control Release 2002; 78: 15-24.

Karikar C, Maitra A, Bisht S , Feldmann G , Soni S , Ravi R. Polymeric nanoparticle encapsulated curcumin (“nanocurcumin”): a novel strategy for human cancer therapy. J. Nanobiotechnol. 2007, 5: 3.

Suresh D, Srinivasan K. Studies on the in vitro absorption of spice principles––Curcumin, capsaicin and piperine in rat intestines. Food Chem. Toxicol. 2007, 45 (8):1437–42.

Ma Z, Shayeganpour A ,Brocks D. R , Lavasanifar A , Samuel J. High-performance liquid chromatography analysis of curcumin in rat plasma: application to pharmacokinetics of polymeric micellar formulation of curcumin. Biomed. Chromatogr. 2007, 21 (5):546–52.

Gupta NK, Dixit V.K. Bioavailability enhancement of curcumin by complexation with Phosphatidylcholine; 100(5):1987-95.

Shen, L, Ji H. F. Theoretical study on physicochemical properties of curcumin.Spectrochin. Acta A Mol. Biomol. Spectrosc. 2007, 67 (3–4):619–23.

Ohori, H , Yamakoshi H, Tomizawa M , Shibuya M , Kakudo Y , Takahashi A , Akashi S, Kato S, Suzuki T, Ishioka C, Iwabuchi Y, Shibata H. Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol. Cancer Ther. 2006, 5 (10): 2563–71.

Belcaro G, Cesarone M.R, Dugall M. Product-evaluation registry of Meriva®, Curcumin-phosphadidylcholine complex, for the complementary management of osteoarthritis, Panminerva Medica 2010 Giugno; 52,2 (1):55-62.

Shimatsu A, Kakeya H, Imaizumi A , Morimoto T, Kanai M, Maeda S . Clinical Application of “Curcumin”, a Multi-Functional Substance, 2012:75-82.

Anand P, Kunnumakkara AB, Newman RA. Bioavailability of curcumin: problems and promises. Mol Pharm 2007, 4(6); 807-18.

Sasaki H, Sunagawa Y, Takahashi K,. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull 2011, 34(5): 660-5.

Frautschy SA, 2011.

Fan X, Zhang C, Liu DB, Yan J, Liang HP .The clinical applications of curcumin: current state and the future, Curr Pharm Des. 2013; 19(11):2011-31.